Cara Therapeutics

About:

Cara Therapeutics is a biotechnology company focused on developing therapeutics to treat diseases associated with pain and inflammation.

Website: http://www.caratherapeutics.com

Twitter/X: caratherapinc

Top Investors: Connecticut Innovations, Mitsubishi UFJ Capital, Mitsubishi Corporation, HealthCare Royalty Partners, Mitsubishi Motors

Description:

Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.

Total Funding Amount:

$517M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Shelton, Connecticut, United States

Founded Date:

2004-07-02

Contact Email:

info(AT)caratherapeutics.com

Founders:

Derek Chalmers, Frederique Menzaghi, Michael E. Lewis

Number of Employees:

101-250

Last Funding Date:

2023-11-02

IPO Status:

Public

© 2025 bioDAO.ai